WILMINGTON, Del. / Dec 02, 2025 / Business Wire / Incyte (Nasdaq:INCY) today announced its partnership with world renowned supermodel and beauty entrepreneur Winnie Harlow — one of the most recognizable people living with vitiligo — to raise awareness of vitiligo through “The Power of Choice” campaign. Vitiligo is a chronic autoimmune condition characterized by loss of pigment in the skin, resulting in white patches that can... Read More

WILMINGTON, Del. / Dec 01, 2025 / Business Wire / Incyte (Nasdaq:INCY) announces the appointment of Richard Hoffman as Executive Vice President and General Counsel effective today, December 1, 2025. In his new role, Mr. Hoffman will serve as a key member of the Executive Leadership Team and be responsible for the Company’s legal and compliance teams. “Richard joins us with a distinguished background, including many years of... Read More

WILMINGTON, Del. / Nov 19, 2025 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of December: Citi’s 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 11:15 am (EST) 8 th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 1:20 pm (EST) The presentations will be webcast live and can be accessed at... Read More

WILMINGTON, Del. / Nov 06, 2025 / Business Wire / Incyte (Nasdaq:INCY) today announced the expansion of its Moments of Clarity program, which amplifies the voices of people living with chronic immune-mediated skin conditions. This year, the initiative introduces six compelling new stories that spotlight the true lived experiences of people living with nonsegmental vitiligo and mild-to-moderate atopic dermatitis (AD), the... Read More

INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated data in essential thrombocythemia (ET) and translational data demonstrating disease modifying activity in both ET and MF. Additionally, the more than 50 abstracts accepted at ASH include new and updated data... Read More

WILMINGTON, Del. / Oct 30, 2025 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00 am (EST) Jefferies Global Healthcare Conference (London) on Tuesday, November 18, 2025 at 11:00 am (GMT) The presentations will be webcast live and can be accessed... Read More

Total revenues of $1.37 billion in the third quarter of 2025, reflecting 20% growth compared to the third quarter of 2024 Jakafi ® (ruxolitinib) net product revenue of $791 million, an increase of 7% compared to the same period in 2024 Opzelura ® (ruxolitinib) cream net product revenue of $188 million, an increase of 35% compared to the prior year period Hematology-Oncology portfolio net product revenues of $171 million,... Read More

Collaboration underscores both companies’ commitment to advancing patient-centric solutions and expanding access to therapies through novel drug delivery technologies WILMINGTON, Del. & CINCINNATI / Oct 27, 2025 / Business Wire / Incyte (NASDAQ:INCY) and Enable Injections, Inc. (“Enable”) today announced a new partnership to develop and commercialize specific assets in Incyte’s portfolio, including its investigational,... Read More

Eight-week results from the TRuE-AD4 trial demonstrate treatment with Opzelura ® (ruxolitinib cream) significantly improved the clinical signs of atopic dermatitis (AD), including improved itch as early as Day 2, and was well tolerated in adults with moderate AD who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) At Week 8, 70% of... Read More

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancer Planned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026 Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal... Read More

WILMINGTON, Del. / Oct 12, 2025 / Business Wire / Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, and INCB161734, a novel, selective and orally bioavailable KRAS G12D inhibitor, will be highlighted as oral presentations at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. “We are... Read More

WILMINGTON, Del. / Oct 08, 2025 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 28, 2025. The schedule for the press release and conference call/webcast is as follows: Q3 2025 Press Release: October 28, 2025 at 7:00 a.m. ET Q3 2025 Conference Call: October 28, 2025 at 8:00 a.m. ET Domestic Dial-In... Read More

WILMINGTON, Del. / Sep 24, 2025 / Business Wire / Incyte (Nasdaq:INCY) announced today equity inducement awards grants to David H. Gardner, the Company’s new Executive Vice President, Chief Strategy Officer, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The awards were approved by the compensation committee of the Company’s Board of Directors as an inducement material to the new employee entering into... Read More

WILMINGTON, Del. / Sep 22, 2025 / Business Wire / Incyte (Nasdaq:INCY) announces that Dave Gardner has been appointed Executive Vice President and Chief Strategy Officer (CSO) effective today, September 22, 2025. In his new role, Mr. Gardner will serve as a key member of the Executive Leadership Team and be responsible for the Company’s strategy and business development. "Dave possesses a unique combination of business... Read More

Opzelura is the first topical JAK inhibitor approved in the U.S. for pediatric atopic dermatitis (AD) Phase 3 data supporting the approval show that treatment with Opzelura resulted in significant efficacy, with no new safety concerns identified This milestone marks the third U.S. approval for Opzelura, which is now indicated to treat mild to moderate AD in non-immunocompromised patients 2+ years of age and nonsegmental... Read More

Across both STOP-HS1 and STOP-HS2, povorcitinib treatment resulted in continued clinically meaningful and statistically significant improvements for patients with active moderate to severe hidradenitis suppurativa (HS) through Week 24 At Week 24, nearly 60% of efficacy-evaluable patients among both povorcitinib treatment groups achieved HiSCR50 Additionally, patients treated with povorcitinib achieved HiSCR75 (31.0%-40.3%),... Read More

24-week data from the Phase 3 STOP-HS clinical trial program of povorcitinib in patients with hidradenitis suppurativa (HS) selected as a late-breaking oral presentation WILMINGTON, Del. / Sep 10, 2025 / Business Wire / Today Incyte (Nasdaq:INCY) announced that it will present new data from its dermatology portfolio at the European Association of Dermatology and Venerology (EADV) 2025 Congress, held from September 17 – 20,... Read More

New awareness campaign features authentic, often misunderstood, stories from people living with hidradenitis suppurativa (HS), highlighting the emotional and physical impact of the condition WILMINGTON, Del. / Sep 03, 2025 / Business Wire / Incyte (Nasdaq:INCY) announced the launch of HS TRUTHS , a new educational campaign aimed at revealing the authentic and often hidden realities of living with hidradenitis suppurativa... Read More

WILMINGTON, Del. / Aug 27, 2025 / Business Wire / Incyte (Nasdaq: INCY) announced today equity inducement awards grants to Soni Basi, the Company’s new Executive Vice President and Chief Human Resources Officer, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The awards were approved by the compensation committee of the Company’s Board of Directors as an inducement material to the new employee entering into... Read More

WILMINGTON, Del. / Aug 25, 2025 / Business Wire / Incyte (Nasdaq:INCY) announces that Soni Basi has been appointed Executive Vice President and Chief Human Resources Officer (CHRO) effective today, August 25, 2025. In her new role, Ms. Basi will serve as a key member of the Executive Leadership Team and be responsible for shaping the Company’s global human resources strategy including talent acquisition, organizational... Read More

WILMINGTON, Del. / Aug 19, 2025 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Cantor Global Healthcare Conference on Wednesday, September 3, 2025 at 8:00 am (EDT) Well Fargo Healthcare Conference on Thursday, September 4, 2025 at 8:45 am (EDT) Morgan Stanley 23 rd Annual Global Healthcare Conference on Tuesday, September 9,... Read More

Company initiates search for successor and reaffirms full year financial guidance WILMINGTON, Del. / Aug 05, 2025 / Business Wire / Incyte (Nasdaq:INCY) today announced that Christiana Stamoulis will step down from her role as Executive Vice President and Chief Financial Officer (CFO) to pursue another opportunity, effective September 16, 2025. Ms. Stamoulis will remain with the Company until then to support a smooth... Read More

Total revenues of $1,216 million in the second quarter (Q2'25) (+16% Y/Y); total product revenues of $1,059 million in Q2'25 (+17%Y/Y) Jakafi ® (ruxolitinib) net product revenues of $764 million in Q2'25 (+8% Y/Y); raising full year 2025 guidance to a new range of $3,000 - $3,050 million [previously $2,950 - $3,000 million] Opzelura ® (ruxolitinib) cream net product revenues of $164 million in Q2'25 (+35% Y/Y) Niktimvo ™... Read More

Mini oral presentation to highlight initial Phase 1 data of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, in patients with advanced or metastatic solid tumors Oral presentation to feature initial data of INCB161734, a novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, in patients with advanced or metastatic solid tumors with KRASG12D mutations WILMINGTON, Del. / Jul 24, 2025 /... Read More

WILMINGTON, Del. / Jul 10, 2025 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number:... Read More

WILMINGTON, Del. / Jul 02, 2025 / Business Wire / Incyte Corporation (Nasdaq: INCY) announced today equity inducement awards grants to Bill Meury in connection with his appointment as the Company’s new President and Chief Executive Officer. The awards are made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and were approved by the compensation committee of the Company’s Board of Directors as an inducement... Read More

Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO Hervé Hoppenot to retire after 11 years of leading Incyte through major expansion Julian Baker elected Chairman of the Board of Directors WILMINGTON, Del. / Jun 26, 2025 / Business Wire / Incyte (Nasdaq:INCY) today announced that the Company’s Board of Directors has unanimously... Read More

WILMINGTON, Del. / Jun 20, 2025 / Business Wire / Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura ® ), a topical Janus kinase (JAK) inhibitor, for the treatment of children 2-11 years old with mild to moderate atopic dermatitis (AD). The Prescription Drug User Fee Act (PDUFA)... Read More

Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide is the first FDA-approved CD19- and CD20-targeted immunotherapy combination for adult patients with follicular lymphoma (FL) Patients with relapsed or refractory FL achieved significantly improved progression-free survival with Monjuvi in combination with rituximab and lenalidomide in the Phase 3 registration trial This milestone represents the second... Read More

Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic response with the majority (82%)... Read More

POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in... Read More

WILMINGTON, Del. / Jun 06, 2025 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 16,550 shares of the Company’s common stock to 19 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of June 2, 2025, and were approved by the compensation committee of... Read More

Late-breaking oral presentation will highlight new data from a trial of INCA033989, an anti-mutant calreticulin (mutCALR)-directed monoclonal antibody, in patients with essential thrombocythemia (ET) Incyte to host an in-person analyst and investor event highlighting the mutCALR data at EHA on Sunday, June 15, 2025, from 6:00 - 7:30 a.m. EDT (12:00 - 1:30 p.m. CEST ) WILMINGTON, Del. / Jun 03, 2025 / Business Wire / Incyte... Read More

WILMINGTON, Del. / May 27, 2025 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025 at 11:20 am (ET). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On. , Incyte follows the science to... Read More

Zynyz ® (retifanlimab-dlwr), a PD-1 inhibitor, is now approved for the treatment of advanced squamous cell carcinoma of the anal canal (SCAC) in combination with chemotherapy and as a monotherapy Patients with SCAC treated with Zynyz achieved a statistically significant improvement in progression-free survival and improvement in overall survival WILMINGTON, Del. / May 15, 2025 / Business Wire / Incyte (Nasdaq:INCY) today... Read More

WILMINGTON, Del. / May 07, 2025 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 33,413 shares of the Company’s common stock and stock option awards to purchase an aggregate of 8,951 shares of the Company’s common stock to 60 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and... Read More

WILMINGTON, Del. / May 01, 2025 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025 at 1:40 pm (PDT). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On. , Incyte follows the... Read More

Total revenues of $1,053 million in the first quarter (Q1'25) (+20% Y/Y); total product revenues of $922 million in Q1'25 (+26%Y/Y) Jakafi ® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to a new range of $2,950 - $3,000 million from $2,925 - $2,975 million Opzelura ® (ruxolitinib) cream net product revenues of $119 million in Q1'25 (+38% Y/Y) Niktimvo ™... Read More

WILMINGTON, Del. / Apr 25, 2025 / Business Wire / Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms,... Read More

WILMINGTON, Del. / Apr 23, 2025 / Business Wire / Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 – June 3, 2025, in Chicago. “The data featured at the 2025 ASCO Annual Meeting, from both our approved medicines and early-stage pipeline, reflect our ongoing efforts... Read More

WILMINGTON, Del. / Apr 10, 2025 / Business Wire / Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q1 2025 Press Release: April 29, 2025 at 7:00 a.m. ET Q1 2025 Conference Call: April 29, 2025 at 8:00 a.m. ET Domestic Dial-In... Read More

WILMINGTON, Del. / Apr 07, 2025 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 20,334 shares of the Company’s common stock to 24 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of April 1, 2025, and were approved by the compensation committee of... Read More

- Statistically significant results for primary endpoints in both STOP-HS1 and STOP-HS2 Phase 3 studies for both doses tested - Favorable safety profile, with no safety concerns - Data will support planned regulatory submission for povorcitinib in hidradenitis suppurativa (HS) worldwide - Incyte to hold an analyst and investor call on Monday, March 17, 2025 from 8:00-9:00 a.m. ET WILMINGTON, Del. / Mar 17, 2025 / Business... Read More

Full data from the Phase 3 TRuE-PN1 study, presented today in a late-breaking oral presentation, showed the study met all primary and key secondary endpoints Topline data from a separate Phase 3 study, TRuE-PN2, showed that while the primary endpoint did not reach statistical significance, the primary and all key secondary endpoints were in favor of ruxolitinib cream 1.5% versus vehicle These Phase 3 data will inform planned... Read More

WILMINGTON, Del. / Mar 07, 2025 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 13,351 shares of the Company’s common stock to 16 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of March 3, 2025, and were approved by the compensation committee of... Read More

Featured abstracts for ruxolitinib cream (Opzelura ® ) include multiple presentations in atopic dermatitis and late-breaking data in prurigo nodularis (PN) Pipeline data presented includes data for axatilimab (Niktimvo™) in patients with dermatologic manifestations of chronic graft-versus-host disease (GVHD) WILMINGTON, Del. / Feb 28, 2025 / Business Wire / Incyte (Nasdaq: INCY) today announced that multiple abstracts... Read More

Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte receives exclusive rights to develop and commercialize collaboration products WILMINGTON, Del. & BURLINGAME, Calif. / Feb 20, 2025 / Business Wire / Incyte (Nasdaq:INCY) and Genesis Therapeutics, Inc. announced today that the companies... Read More

WILMINGTON, Del. / Feb 18, 2025 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen 45 th Annual Health Care Conference on Monday, March 3, 2025 at 11:10 am (EST) Leerink Partners 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 9:20 am (EST) The presentations will be webcast live and can be accessed at... Read More

Total revenues of $1.2 billion (+16% Y/Y) in the fourth quarter 2024 and $4.2 billion (+15% Y/Y) for the full year 2024 Jakafi ® (ruxolitinib) net revenues of $773 million (+11% Y/Y) in the fourth quarter 2024 and $2.8 billion (+8% Y/Y) for the full year 2024; Jakafi net revenues guidance range of $2,925 - $2,975 million for the full year 2025 Opzelura ® (ruxolitinib) cream net revenues of $162 million (+48% Y/Y) in the... Read More

WILMINGTON, Del. / Feb 07, 2025 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 16,301 shares of the Company’s common stock to 24 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of February 3, 2025, and were approved by the compensation committee... Read More

WILMINGTON, Del. / Jan 21, 2025 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 8:00 a.m. ET on Monday, February 10, 2025. The schedule for the press release and conference call/webcast is as follows: • Q4 & YE 2024 Press Release: February 10, 2025 at 7:00 a.m. ET • Q4 & YE 2024 Conference Call: February 10,... Read More

2025 will be a transformational year for Incyte with multiple significant milestones, including four potential launches, four pivotal trial readouts, seven proof of concept data readouts and at least three Phase 3 study initiations Well-positioned for long-term growth, the Company has the potential to deliver more than 10 high impact launches across its portfolio by 2030 WILMINGTON, Del. / Jan 13, 2025 / Business Wire /... Read More

WILMINGTON, Del. / Dec 17, 2024 / Business Wire / Incyte (Nasdaq: INCY) announced today that it will present at the 43 rd Annual J. P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 am (PST). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On. , Incyte follows... Read More

The pivotal Phase 3 inMIND trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints in patients with relapsed or refractory follicular lymphoma (FL) treated with tafasitamab (Monjuvi ® ) in combination with lenalidomide and rituximab Positive data featured in a late-breaking oral presentation at the 2024 American Society of Hematology (ASH) Annual Meeting support the planned U.S. filing... Read More

Phase 3 POD1UM-304 trial met primary endpoint of overall survival (OS) and all secondary endpoints in patients with previously untreated metastatic non-small cell lung cancer (NSCLC) Data presented at the European Society for Medical Oncology (ESMO) Asia Congress 2024 support the planned 2025 filing of a supplemental Biologics License Application (sBLA) in the U.S. for retifanlimab in NSCLC WILMINGTON, Del. / Dec 07, 2024 /... Read More

WILMINGTON, Del. / Dec 06, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 7,259 shares of the Company’s common stock to 15 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of December 2, 2024, and were approved by the compensation committee... Read More

WILMINGTON, Del. / Nov 26, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will now present at Citi’s 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 8:00 a.m. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On. , Incyte follows the science... Read More

Twenty presentations, including late-breaking, oral and poster presentations, highlight advances across seven of the company’s medicines Late-breaking data presentation at ASH will feature results from the Phase 3 inMIND study evaluating tafasitamab in follicular lymphoma (FL); data to be highlighted during ASH press program Incyte to host virtual analyst and investor event on Thursday, December 12, 2024, from 4:00-5:00 p.m.... Read More

WILMINGTON, Del. / Nov 18, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU). The decision was made following the observation of certain in vivo preclinical toxicology findings. These data have been shared with the U.S. Food and Drug Administration (FDA) and Incyte will work closely with the FDA... Read More

WILMINGTON, Del. / Nov 14, 2024 / Business Wire / Incyte (Nasdaq: INCY) announced today that it will present at Citi’s 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 3:15 p.m. in Miami. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On. , Incyte follows the... Read More

WILMINGTON, Del. / Nov 07, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 33,003 shares of the Company’s common stock and stock option awards to purchase an aggregate of 15,812 shares of the Company’s common stock to 27 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date... Read More

WILMINGTON, Del. / Oct 30, 2024 / Business Wire / Incyte (Nasdaq: INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim’s Inaugural Healthcare Innovation Conference on Monday, November 11, 2024 at 2:00 pm (EST) Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 9:30 am (GMT) The presentations will be webcast live and can be accessed at... Read More

Total revenues of $1,138 million in the third quarter (Q3'24) (+24% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $741 million in Q3'24 (+16% Y/Y); raising full year 2024 Jakafi guidance to a new range of $2,740 - $2,770 million Opzelura ® (ruxolitinib) cream net product revenues of $139 million in Q3'24 (+52% Y/Y); launch momentum continues in the U.S. supported by reimbursement expansion in Europe Niktimvo™... Read More

Recognition Among Several Workplace Awards Received by the Company this Year WILMINGTON, Del. / Oct 24, 2024 / Business Wire / Incyte announced today that for the seventh consecutive year, it has been named a top five biotech and pharma employer based on Science magazine’s annual survey. This year, Incyte was ranked third and specifically recognized for its commitment to employee respect, social responsibility and employee... Read More

Board-certified dermatologist, Dr. Sandra Lee, widely known as Dr. Pimple Popper, among others, details her journey with mild-moderate atopic dermatitis, the most common form of eczema, and her experience on Opzelura ® (ruxolitinib) cream 1.5% WILMINGTON, Del. / Oct 10, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today the expansion of its Moments of Clarity program, an educational initiative highlighting stories... Read More

WILMINGTON, Del. / Oct 08, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 29, 2024. The schedule for the press release and conference call/webcast is as follows: • Q3 2024 Press Release: October 29, 2024 at 7:00 a.m. ET • Q3 2024 Conference Call: October 29, 2024 at 8:00 a.m. ET • Domestic... Read More

WILMINGTON, Del. / Oct 07, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 22,107 shares of the Company’s common stock to 26 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of October 1, 2024, and were approved by the compensation committee... Read More

WILMINGTON, Del. / Oct 03, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced that today it granted an equity inducement award to Lee Heeson, the Company’s new Executive Vice President, Incyte International, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The award was approved by the compensation committee of the Company’s Board of Directors as an inducement material to Mr. Heeson entering into employment... Read More

WILMINGTON, Del. / Sep 25, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that key data from across its dermatology portfolio, including multiple late-breaking abstracts, will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2024 held September 25-28 in Amsterdam. “We’re excited to present five late-breaking oral presentations at this year’s congress, featuring data... Read More

New antitumor response data from a range of doses and regimens unveiled today at Incyte investor event These results build upon safety and tolerability data presented earlier today during a mini-oral presentation at the European Society of Medical Oncology (ESMO) Congress 2024 Findings support the initiation of a pivotal trial in ovarian cancer, expected to begin in 2025; additional plans to evaluate INCB123667 in... Read More

Phase 3 POD1UM-303/InterAACT2 trial met primary endpoint of progression-free survival and demonstrated improvement across secondary endpoints in patients with squamous cell anal carcinoma (SCAC) taking retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) Late-breaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024 support the planned U.S. filing of a... Read More

WILMINGTON, Del. / Sep 09, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 11,497 shares of the Company’s common stock to 14 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of September 3, 2024, and were approved by the compensation... Read More

Presidential Symposium to feature Phase 3 retifanlimab (Zynyz ® ) results in squamous cell anal carcinoma (SCAC); filing of supplemental Biologics License Application (sBLA) in SCAC planned by year end 2024 Mini oral presentation to highlight initial Phase 1 data from potential first-in-class CDK2 inhibitor program in patients with CCNE1 ovarian and other advanced cancers Incyte to host an in-person analyst and investor... Read More

Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi ® ) or placebo in combination with lenalidomide and rituximab met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL) Based on these results, Incyte expects to file a supplemental Biologics License Application for tafasitamab in combination with lenalidomide and rituximab in FL by the end of... Read More

Niktimvo™ (axatilimab-csfr) is the first approved anti-CSF-1R antibody targeting the drivers of inflammation and fibrosis seen in chronic GVHD Pivotal data from the AGAVE-201 study supporting the approval show treatment with Niktimvo resulted in durable responses across all organs studied and patient subgroups Syndax conference call and webcast scheduled for today at 6:00 p.m. ET WILMINGTON, Del. & WALTHAM, Mass. / Aug 14,... Read More

WILMINGTON, Del. / Aug 13, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 at 12:45 pm (EDT) Morgan Stanley 22 nd Annual Global Healthcare Conference on Friday, September 6, 2024 at 10:45 am (EDT) Cantor Global Healthcare Conference on Thursday, September 19,... Read More

WILMINGTON, Del. / Aug 07, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 7,009 shares of the Company’s common stock to 19 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of August 1, 2024, and were approved by the compensation committee of... Read More

Total revenues of $1,044 million in the second quarter (Q2'24) (+9% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $706 million in Q2'24 (+3% Y/Y), total patients increased +7% Y/Y; raising the bottom end of full year 2024 guidance to a new range of $2,710 - $2,750 million Opzelura ® (ruxolitinib) net product revenues of $122 million in Q2'24 (+52% Y/Y); continued uptake in atopic dermatitis (AD) and vitiligo in the... Read More

WILMINGTON, Del. / Jul 09, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 30, 2024. The schedule for the press release and conference call/webcast is as follows: Q2 2024 Press Release: July 30, 2024 at 7:00 a.m. ET Q2 2024 Conference Call: July 30, 2024 at 8:00 a.m. ET Domestic Dial-In Number:... Read More

WILMINGTON, Del. / Jul 08, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 14,577 shares of the Company’s common stock and stock option awards to purchase an aggregate of 18,149 shares of the Company’s common stock to 27 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date... Read More

WILMINGTON, Del. / Jun 13, 2024 / Business Wire / Incyte Corporation (Nasdaq: INCY) (“Incyte” or the “Company”) announced today the final results of its modified “Dutch auction” tender offer to purchase up to $1.672 billion in value of shares of its common stock, which expired at 12:00 midnight, at the end of the day, New York City time, on June 10, 2024. Based on the final count by Computershare Trust Company, N.A., the... Read More

WILMINGTON, Del. / Jun 11, 2024 / Business Wire / Incyte Corporation (Nasdaq: INCY) (“Incyte” or the “Company”) announced today the preliminary results of its modified “Dutch auction” tender offer to purchase up to $1.672 billion in value of shares of its common stock, which expired at 12:00 midnight, at the end of the day, New York City time, on June 10, 2024. Based on the preliminary count by Computershare Trust Company,... Read More

WILMINGTON, Del. / Jun 07, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 14,090 shares of the Company’s common stock and stock option awards to purchase an aggregate of 9,238 shares of the Company’s common stock to 17 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and... Read More

Acquisition strengthens Incyte’s Inflammation and Autoimmunity (IAI) pipeline and reinforces commitment to bring innovative solutions to patients WILMINGTON, Del. & SAN DIEGO / May 30, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that it has completed its acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic... Read More

WILMINGTON, Del. / May 21, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced the expansion of its presence in Delaware with the acquisition of two buildings at 1100 North King Street and 1100 North French Street in downtown Wilmington. This acquisition marks Incyte’s fourth expansion in Delaware since establishing operations in Alapocas in 2014. The new buildings will allow the Company’s U.S.-based teams to be... Read More

WILMINGTON, Del. / May 21, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 45 th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. (EDT) in Miami. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On. ,... Read More

WILMINGTON, Del. / May 14, 2024 / Business Wire / Incyte (Nasdaq: INCY) today announced that several abstracts featuring data from its oncology portfolio will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held May 31 – June 4 in Chicago, and at the European Hematology Association 2024 (EHA2024) Congress held on June 13-16 in Madrid, Spain, and virtually. "The data being... Read More

Incyte commences Dutch Auction tender offer to repurchase up to $1.67 billion of outstanding common shares WILMINGTON, Del. / May 13, 2024 / Business Wire / Incyte Corporation (Nasdaq:INCY) (the “Company”) today announced that its Board of Directors approved a share repurchase authorization of $2.0 billion. The Company has commenced a modified “Dutch Auction” tender offer to repurchase shares of its common stock for an... Read More

WILMINGTON, Del. / May 02, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:00 a.m. (PDT) in Las Vegas. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve... Read More

Total revenues of $881 million in the first quarter (Q1'24) (+9% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $572 million in Q1'24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of $2,690 - $2,750 million Opzelura ® (ruxolitinib) net product revenues of $86 million (+52% Y/Y) in Q1'24; continued uptake in atopic dermatitis (AD) and vitiligo Incyte to acquire Escient Pharmaceuticals and... Read More

EP262, a first-in-class oral Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist with the potential to treat a broad range of inflammatory disorders, has demonstrated proof-of-mechanism in chronic inducible urticaria and is in a Phase 2 study for chronic spontaneous urticaria EP547 is a first-in-class oral MRGPRX4 antagonist with the potential to treat cholestatic pruritus and other conditions with severe pruritus... Read More

WILMINGTON, Del. / Apr 11, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2024. The schedule for the press release and conference call/webcast is as follows: • Q1 2024 Press Release: April 30, 2024 at 7:00 a.m. ET • Q1 2024 Conference Call: April 30, 2024 at 8:00 a.m. ET • Domestic Dial-In... Read More

Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria WILMINGTON, Del. and HONG KONG / Apr 01, 2024 / Business Wire / Incyte (Nasdaq:INCY) (“Incyte”) and China Medical System Holdings Limited (“CMS” or the “Group”) are pleased... Read More

WILMINGTON, Del. / Mar 29, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it granted equity inducement awards to Matteo Trotta, the Company’s new Executive Vice President and General Manager of U.S. Dermatology, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The awards were approved by the compensation committee of the Company’s Board of Directors as an inducement material to the new... Read More

Randomized Phase 2 study met the primary endpoint in patents with hidradenitis suppurativa (HS), reinforcing efficacy and safety profile of ruxolitinib cream Results presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting WILMINGTON, Del. / Mar 10, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced new results from a Phase 2 study evaluating the efficacy and safety... Read More

Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib’s potential role in treating prurigo nodularis (PN) Results presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting marks Incyte’s first presentation of data in PN WILMINGTON, Del. / Mar 10, 2024 / Business Wire / Incyte... Read More

Two late-breaking abstracts have been accepted for oral presentation, including randomized studies evaluating ruxolitinib cream (Opzelura ® ) in hidradenitis suppurativa and povorcitinib (INCB54707) in prurigo nodularis Analyst and investor event to discuss key data presentations scheduled for Monday, March 11, 2024 at 9:00 a.m. PT / 12:00 p.m. ET WILMINGTON, Del. / Mar 04, 2024 / Business Wire / Incyte (Nasdaq:INCY) today... Read More

The Unseen Journey brings to life the often-misunderstood impact of common myeloproliferative neoplasm (MPN) symptoms through AI-generated images developed from the words and experiences of real patients WILMINGTON, Del. / Feb 29, 2024 / Business Wire / Incyte (Nasdaq: INCY) today announced the launch of The Unseen Journey , a... Read More

Priority Review acceptance based on positive results of AGAVE-201 study WILMINGTON, Del. / Feb 27, 2024 / Business Wire / Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of... Read More

WILMINGTON, Del. / Feb 15, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the Cowen 44 th Annual Health Care Conference on Monday, March 4, 2024 at 9:50 a.m. (EST) in Boston. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On. , Incyte... Read More

Total FY'23 net product and royalty revenues of $3.7 billion (+14% Y/Y); total FY'23 net product revenues of $3.2 billion (+15% Y/Y) Jakafi ® (ruxolitinib) net revenues of $2.6 billion (+8%) for FY'23; Jakafi net revenues guidance range of $2,690 - $2,750 million for FY 2024 Opzelura ® (ruxolitinib) cream net revenues of $109 million in Q4'23 and $338 million for FY'23, driven by strong demand in atopic dermatitis and the... Read More

Tafasitamab is approved in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and is currently in Phase 3 trials for multiple indications WILMINGTON, Del. / Feb 05, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced it has entered into an asset purchase agreement with MorphoSys AG (FSE: MOR; NASDAQ: MOR) which gives Incyte exclusive global rights for... Read More

WILMINGTON, Del. / Jan 23, 2024 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 13, 2024. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2023 Press Release: February 13, 2024 at 7:00 a.m. ET Q4 & YE 2023 Conference Call: February 13, 2024... Read More

Presentation underscores potential of several high-impact launches across Oncology and Inflammation & Autoimmunity to drive sustainable long-term growth Company announces new positive topline results from Phase 2 trial evaluating ruxolitinib cream (Opzelura ® ) in adults with hidradenitis suppurativa (HS) Overview of early pipeline, including preliminary results from Phase 1 study of INCB123667 (CDK2i), will also be... Read More

WILMINGTON, Del. / Dec 12, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January: Goldman Sachs Annual Healthcare CEOs Unscripted Conference: A View from the Top on Thursday, January 4, 2024 at 9:30 am (EST) 42 nd Annual J. P. Morgan Healthcare Conference on Monday, January 8, 2024 at 7:30 am (PST) The presentations will be webcast... Read More

Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment Data are featured in the Plenary Scientific Session at the 65 th American Society of Hematology Annual Meeting 2023 Incyte and its partner Syndax expect to file a Biologics License Application (BLA) for axatilimab by year-end 2023 WILMINGTON, Del.... Read More

Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company’s medicines Plenary Scientific Session will feature the full data from AGAVE-201 evaluating axatilimab, an anti-CSFR-1R monoclonal antibody, in patients with chronic graft-versus-host disease (GVHD) Incyte to host an in-person analyst and investor event on Monday, December 11, 2023 from... Read More

Total revenues of $919 million in the third quarter (Q3'23) (+12% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $636 million (+3% Y/Y) in Q3'23, $1.9 billion (+8% Y/Y) YTD 2023, driven by growth in total patients across all indications; tightening full year 2023 guidance to a new range of $2.59 - $2.62 billion Opzelura ® (ruxolitinib) cream net product revenues of $92 million (+141% Y/Y) in Q3'23, $229 million YTD... Read More

WILMINGTON, Del. / Oct 27, 2023 / Business Wire / Science magazine announced today that for the sixth consecutive year, Incyte has been named a top five employer based on its annual survey of approximately 6,800 individuals. Incyte ranked second on this year’s list, two spots higher than its 2022 ranking, and was specifically recognized for its loyal employees, social responsibility and treating employees with respect.... Read More

WILMINGTON, Del. / Oct 18, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Securities 5 th Annual Inflammation, Neurology & Immunology (INI) Conference on Tuesday, November 7, 2023 at 1:10 pm (EST) Evercore ISI 6 th Annual HealthCONx Conference on Thursday, November 30, 2023 at 12:30 pm (EST) The presentations will... Read More

WILMINGTON, Del. / Oct 16, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that abstracts featuring new data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid. "We look forward to sharing data from our oncology portfolio with the scientific community at this year’s ESMO Congress,” said Steven Stein, M.D., Chief... Read More

In the TRuE-AD3 trial, children (age ≥2 to <12 years old) with atopic dermatitis (AD) treated with ruxolitinib cream achieved significant efficacy, as defined by the Investigator’s Global Assessment-treatment success (IGA-TS), following eight weeks of treatment In a second study, treatment with ruxolitinib cream over eight weeks under maximum-use conditions was well tolerated in children (age ≥2 to <12 years) Data were... Read More

WILMINGTON, Del. / Oct 13, 2023 / Business Wire / I ncyte (Nasdaq:INCY) today announced that multiple abstracts featuring new data from the company’s clinical program on povorcitinib, an investigational oral JAK-1 inhibitor, have been accepted for oral presentation at the 8 th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) held October 13-15 in Phoenix. “We look forward to sharing data from three oral... Read More

Patients who initially experienced limited or no facial or total body repigmentation at six months achieved improved repigmentation after continued treatment with Opzelura for up to two years Results were presented in a late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Congress 2023 WILMINGTON, Del. / Oct 11, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced new results of a... Read More

WILMINGTON, Del. / Oct 11, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today its partnership with actress, singer and songwriter Mandy Moore on Moments of Clarity , an educational initiative highlighting the authentic stories of people living with mild to moderate atopic dermatitis (AD) and their journey to finding... Read More

Longer-term use of povorcitinib resulted in further improvement in total body and facial repigmentation Results were presented in a late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Congress 2023 WILMINGTON, Del. / Oct 11, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced new 52-week data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib... Read More

WILMINGTON, Del. / Oct 10, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 31, 2023. The schedule for the press release and conference call/webcast is as follows: Q3 2023 Press Release: October 31, 2023 at 7:00 a.m. ET Q3 2023 Conference Call: October 31, 2023 at 8:00 a.m. ET Domestic Dial-In... Read More

WILMINGTON, Del. / Sep 29, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and... Read More

WILMINGTON, Del. / Aug 22, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Wells Fargo 2023 Healthcare Conference on Thursday, September 7, 2023 at 8:45 am (EDT) Morgan Stanley 21 st Annual Global Healthcare Conference on Monday, September 11, 2023 at 11:20 am (EDT) Bank of America 2023 Global Healthcare Conference on... Read More

Total net product revenues of $827 million in the second quarter (Q2'23) (+25% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $682 million (+14% Y/Y) in Q2'23; raising the bottom end of full year guidance to a new range of $2.58 - $2.63 billion for FY 2023 Opzelura ® (ruxolitinib) cream net product revenues of $80 million (+384% Y/Y) in Q2'23; continued uptake in atopic dermatitis (AD) and vitiligo Two pivotal studies... Read More

Initial study in the neoadjuvant setting designed to assess RP1 in combination with the small molecule, oral PD-L1 inhibitor, INCB99280 WOBURN, Mass. & WILMINGTON, Del. / Jul 31, 2023 / Business Wire / Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical... Read More

Phase 3 TruE-AD3 Study met its primary endpoint WILMINGTON, Del. / Jul 11, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura ® ) in children (age ≥2 to <12 years) with atopic dermatitis (AD). The study met its primary endpoint and showed significantly... Read More

WILMINGTON, Del. / Jul 11, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 1, 2023. The schedule for the press release and conference call/webcast is as follows: Q2 2023 Press Release: August 1, 2023 at 7:00 a.m. ET Q2 2023 Conference Call: August 1, 2023 at 8:00 a.m. ET Domestic Dial-In... Read More

WILMINGTON, Del. / May 25, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting held June 2-6 in Chicago, and at the European Hematology Association 2023 (EHA2023) Hybrid Congress held in Frankfurt, Germany, from June 8-11 and virtually from June... Read More

WILMINGTON, Del. / May 23, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: William Blair 43 rd Annual Growth Stock Conference on Tuesday, June 6, 2023 at 11:20 a.m. (CDT) Goldman Sachs 44 th Annual Global Healthcare Conference on Monday, June 12, 2023 at 8:40 a.m. (PDT) The presentations will be webcast live and can be accessed... Read More

Dr. Cagnoni joins Incyte’s Executive Team as President and Head of Research & Development WILMINGTON, Del. / May 08, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D. President and Head of Research & Development (R&D) effective June 5, 2023. In this role and as a member of the Executive Team, Dr. Cagnoni will lead Incyte’s R&D efforts across... Read More

Total net product revenues of $693 million in Q1'23 (+14% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $580 million (+7% Y/Y) in Q1'23; raising the bottom end of full year guidance to new range of $2.55 - $2.63 billion for FY 2023 Opzelura ® (ruxolitinib) cream approved as the first and only treatment for repigmentation of nonsegmental vitiligo in Europe; continued strong U.S. launch in atopic dermatitis and vitiligo... Read More

Adult patients with atopic dermatitis treated with Opzelura experienced rapid and substantial improvement in itch, which was sustained through Day 28 WILMINGTON, Del. / May 01, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of Opzelura ® (ruxolitinib) cream 1.5% to control pruritus (itching) and reduce disease severity in... Read More

Opzelura ® (ruxolitinib) Cream is the first approved treatment in the European Union (EU) to address repigmentation in non-segmental vitiligo Phase 3 data supporting the approval show treatment with Opzelura resulted in improved facial and total body repigmentation, sustained and continued improvements with longer duration of treatment WILMINGTON, Del. / Apr 20, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced... Read More

WILMINGTON, Del. / Apr 18, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: Bank of America 2023 Health Care Conference on Wednesday, May 10, 2023 at 10:40 a.m. (PDT) 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 at 10:30 a.m. (EDT) The presentations will be webcast live and can be accessed at... Read More

Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 BOSTON & WILMINGTON, Del. / Apr 16, 2023 / Business Wire / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (Nasdaq: INCY) today announced final five-year follow-up data from the Phase 2 L-MIND study showing that... Read More

WILMINGTON, Del. / Apr 11, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 2, 2023. The schedule for the press release and conference call/webcast is as follows: Q1 2023 Press Release: May 2, 2023 at 7:00 a.m. ET Q1 2023 Conference Call: May 2, 2023 at 8:00 a.m. ET Domestic Dial-In Number:... Read More

WILMINGTON, Del. & TOKYO / Mar 27, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre ® (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of myeloid/lymphoid neoplasms (MLNs) with FGFR1 fusion (also known as 8p11 myeloproliferative syndrome). MLNs are a rare, aggressive group of... Read More

WILMINGTON, Del. / Mar 23, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD) use in the treatment of certain types of myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD). The complete response letter states that... Read More

First regulatory approval for Incyte PD-1 inhibitor based on the results of the POD1UM-201 trial Zynyz is also being studied in additional tumor types and in combination with other Incyte pipeline compounds WILMINGTON, Del. / Mar 22, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz ™ (retifanlimab-dlwr), a humanized monoclonal antibody targeting... Read More

WILMINGTON, Del. / Mar 18, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo. These data were presented today in a late-breaking oral presentation (Session: S042 – Late-Breaking Research: Session 2) at the 2023 American... Read More

WILMINGTON, Del. / Mar 18, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced new 104-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Opzelura ® (ruxolitinib) cream 1.5% in patients 12 years of age and older with nonsegmental vitiligo, a chronic autoimmune disease characterized by depigmentation of skin. These data were presented today in two late-breaking oral presentations (Session:... Read More

WILMINGTON, Del. / Mar 14, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida. “As Incyte continues to advance research in areas where we believe we can have the biggest impact for patients, we look forward to... Read More

IRVING, Texas , March 7, 2023 /PRNewswire/ -- Caris Life Sciences ® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced a strategic research partnership with Incyte Corporation (NASDAQ:INCY) to augment precision medicine approaches for Incyte's oncology pipeline. Caris' unique platform combines data from whole exome... Read More

WILMINGTON, Del. / Mar 06, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting, held March 17-21, 2023, in New Orleans. New data from the Phase 3 TRuE-V clinical trial program evaluating the durability and long-term response (up to 104 weeks) of Opzelura ®... Read More

WILMINGTON, Del. / Mar 03, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that it will discontinue the Phase 3 LIMBER-304 trial following results of a pre-planned interim analysis conducted by an independent data monitoring committee (IDMC) indicating that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population. The recommendation to stop the study was not due to safety.... Read More

WILMINGTON, Del. / Feb 24, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of ruxolitinib cream (Opzelura™) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. “The positive CHMP opinion brings us one... Read More

WILMINGTON, Del. / Feb 16, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the Cowen 43 rd Annual Health Care Conference on Monday, March 6, 2023 at 11:10 a.m. (EST) in Boston. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company... Read More

WILMINGTON, Del. / Feb 10, 2023 / Business Wire / Incyte (Nasdaq:INCY) today announced new 52-week results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (formerly INCB54707), an oral JAK1 inhibitor, in adult patients with hidradenitis suppurativa (HS). These data were presented as an oral presentation (Abstract #258) at the 12th Conference of the European Hidradenitis Suppurativa Foundation, held... Read More

WILMINGTON, Del. / Jan 24, 2023 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the Guggenheim Healthcare Talks l Oncology Day on Wednesday, February 8, 2023 at 1:35 p.m. (EST) in New York. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical... Read More

Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2022 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 7, 2023. The schedule for the press release and conference call/webcast is as follows: Q4 & YE 2022 Press Release: February 7, 2023 at 7:00 a.m. ET Q4 & YE 2022 Conference Call: February 7, 2023 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042... Read More

INCA033989, a new anti-mutant calreticulin (CALR)-targeted monoclonal antibody, represents important research milestone in myelofibrosis (MF) and essential thrombocythemia (ET) INCA033989 abstract selected as one of only six ASH plenary presentations INCA033989 clinical trials to begin in 2023 Research highlights Incyte’s discovery capabilities and progress of its LIMBER program evaluating new targets and combinations for... Read More

Phase 2 data demonstrate that the addition of parsaclisib to ruxolitinib (Jakafi ® ) resulted in spleen volume reduction and improvement in symptom burden in patients with myelofibrosis (MF) Initial results of a Phase 1/2 study evaluating the safety and tolerability of INCB00928, an ALK2 inhibitor, show INCB00928 improves anemia in patients with MF both as monotherapy and in combination with ruxolitinib These studies are... Read More